Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bristol-Myers Squibb Co (BMY) vs Logitech International SA (LOGI) Price & Performance

Bristol-Myers Squibb CoTrade
Logitech International SATrade

Price performance (Past 24H)

Key statistics

Bristol-Myers Squibb Co vs Logitech International SA — how do they compare? Bristol-Myers Squibb Co trades at $63.67 (market cap $129.94B), while Logitech International SA trades at $103.79 (market cap $14.96B). The key difference: Bristol-Myers Squibb Co is far larger — about 8.7× Logitech International SA's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.

BMYLOGI
Market Cap
$129.94B$14.96B
Sector
HealthTechnology
52-Week High
$65.89$126.69
52-Week Low
$42.60$85.84
Enterprise Value
$163.92B$13.30B
Dividend Yield
3.96%1.64%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bristol-Myers Squibb Co

Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.

BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.

Logitech International SA

Logitech (LOGI) trades at $103.28, down 1.52% on the day, with a bearish technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat expectations with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand. However, a semiconductor supplier shutdown poses near-term supply chain risks. The stock shows strong profitability with a net margin of 16.28% and ROE of 35.29%, but valuation multiples like P/E of 19.03 and P/S of 3.1 suggest moderate pricing.

Outlook is cautious due to supply constraints overshadowing solid fundamentals. The consensus price target is $109.75, offering ~6% upside, but investor sentiment is divided with equal buy and sell ratings. Key risks include execution on supply chain mitigation and competitive pressures in the gaming and peripherals market. Near-term performance hinges on resolving supplier issues to meet robust demand.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bristol-Myers Squibb Co

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Read more on BMY

About Logitech International SA

Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.

Read more on LOGI